Poïesis is focused on sourcing late-stage or approved products from human R&D and evaluating their viability for in-licensing to develop for the veterinary market

Poïesis has agreed to licensing terms to acquire the veterinary IP rights for assets focused on the treatment of cancers in dogs and cats.

We are working closely with the biotechnology company that is developing this product for use in humans, which allows Poïesis unprecedented access to data and drug product for clinical trials.

We continue to evaluate novel therapeutics that we encounter which may address unmet or poorly served needs in the pet medicines market.